— Know what they know.
Not Investment Advice

INNO.CN CNQ

InnoCan Pharma Corporation
1W: -7.6% 1M: +1.4% 3M: -17.9% YTD: -69.4% 1Y: -84.6% 3Y: -84.6% 5Y: -93.2%
C$2.20 ($1.54)
-0.15 (-6.38%)
 
CNQ · Healthcare · Medical - Pharmaceuticals · Tech Score Neutral · Power 53 · C$9.9M mcap · 4M float · 0.039% daily turnover

Balance Sheet Trends

Total Assets
$9M +33.4% ▲
5Y CAGR: +29.1%
Total Liabilities
$2M -12.4% ▼
5Y CAGR: +13.9%
Shareholders Equity
$5M +25.9% ▲
5Y CAGR: +29.6%
Cash & Investments
$5M +28.9% ▲
5Y CAGR: +20.5%
Total Debt
$10K -69.7% ▼
5Y CAGR: -32.6%
Net Debt
-$5M -29.8% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2020FY2021FY2022FY2023FY2024
— Assets —
Cash$2M$11M$5M$4M$5M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$2M$11M$5M$4M$5M
Net Receivables$1M$0$62K$249K$250K
Inventory$430K$510K$1M$2M$3M
Other Current Assets$182K$248K$285K$583K$505K
Total Current Assets$4M$13M$7M$7M$9M
Property, Plant & Equip.$56K$54K$98K$136K$113K
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets-$56K-$54K-$98K$0$0
Total Non-Current Assets$56K$54K$98K$136K$113K
Total Assets$4M$13M$7M$7M$9M
— Liabilities —
Accounts Payable$527K$53K$95K$112K$185K
Short-Term Debt$0$0$0$0$0
Deferred Revenue$384K$432K$0$0$0
Other Current Liabilities$7M$3M$304K$2M$2M
Total Current Liabilities$8M$4M$731K$3M$2M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$0$0$0$0$0
Total Non-Current Liabilities$1K$0$20K$11K$0
Total Liabilities$8M$4M$751K$3M$2M
— Equity —
Common Stock$0$0$0$0$0
Retained Earnings-$15M-$25M-$28M-$33M-$35M
Accumulated OCI$0$0-$0$0$0
Total Stockholders Equity-$4M$9M$6M$4M$5M
Total Liabilities & Equity$4M$13M$7M$7M$9M
— Key Metrics —
Total Debt$38K$1K$34K$33K$10K
Net Debt-$2M-$11M-$5M-$4M-$5M
Total Investments$0$0$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms